Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/22/21 | $20,000,000 | Series A |
CTS Capital GF Xinde Investment Lanhu Capital Ming BioVentures New Alliance Capital Oriza Holdings YuanBio Venture Capital  | undisclosed |
